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Allopurinol Use Yields Potentially Beneficial Effects on
Inflammatory Indices in Those With Recent Ischemic Stroke
A Randomized, Double-Blind, Placebo-Controlled Trial
Scott W. Muir, MRCP; Craig Harrow, MRCP; Jesse Dawson, MRCP; Kennedy R. Lees, MD, FRCP;
Christopher J. Weir, PhD; Naveed Sattar, PhD, FRCP; Matthew R. Walters, MD, FRCP
Background and Purpose—Elevated serum uric acid level is associated with poor outcome and increased risk of recurrent
events after stroke. The xanthine oxidase inhibitor allopurinol lowers uric acid but also attenuates expression of
inflammatory adhesion molecules in murine models, reduces oxidative stress in the vasculature, and improves
endothelial function. We sought to investigate whether allopurinol alters expression of inflammatory markers after acute
ischemic stroke.
Methods—We performed a randomized, double-blind, placebo-controlled trial to investigate the safety, tolerability, and
effect of 6 weeks’ treatment with high- (300 mg once a day) or low- (100 mg once a day) dose allopurinol on levels
of uric acid and circulating inflammatory markers after ischemic stroke.
Results—We enrolled 50 patients with acute ischemic stroke (17, 17, and 16 in the high, low, and placebo groups,
respectively). Mean (SD) age was 70 (13) years. Groups had similar characteristics at baseline. There were no
serious adverse events. Uric acid levels were significantly reduced at both 7 days and 6 weeks in the high-dose group
(by 0.14 mmol/L at 6 weeks, P0.002). Intercellular adhesion molecule-1 concentration (ng/mL) rose by 51.2 in the
placebo group, rose slightly (by 10.6) in the low-dose allopurinol group, but fell in the high-dose group (by 2.6;
difference between groups P0.012, Kruskal-Wallis test).
Conclusion—Allopurinol treatment is well tolerated and attenuates the rise in intercellular adhesion molecule-1 levels seen
after stroke. Uric acid levels were lowered with high doses. These findings support further evaluation of allopurinol as
a preventive measure after stroke. (Stroke. 2008;39:3303-3307.)
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A wealth of epidemiological data shows that elevatedserum uric acid (UA) level is associated with an in-
creased risk of vascular events,1 including in the poststroke
period.2 An association between elevated UA and worse
outcome after stroke has been observed,1,3 although discor-
dant reports exist.4 The uricosuric effects of the angiotensin
receptor blocker losartan may contribute to its greater benefit
compared with atenolol with regard to stroke reduction.5
Furthermore, use of xanthine oxidase inhibition may yield
additional benefits in addition to potent UA reduction. Allo-
purinol, the most commonly used xanthine oxidase inhibitor,
reduces oxidative stress in the vasculature,6 improves endo-
thelial function in a variety of cardiovascular disease states,7
and reduces expression of proinflammatory molecules such
as soluble intercellular adhesion molecule-1 (ICAM-1) in
vitro.8 Allopurinol has not yet been studied in the poststroke
setting.
We investigated the effect of allopurinol on levels of UA
and circulating inflammatory markers in a group of patients
with recent ischemic stroke.
Methods
We performed a prospective randomized, double-blind, placebo-
controlled study. Patients were recruited within 72 hours of radio-
logically confirmed ischemic stroke. Exclusion criteria were a
contraindication to allopurinol treatment, serum creatinine concen-
tration 200 mol/L, concurrent warfarin treatment, and comorbid-
ity likely to cause death within 3 months. Patients were randomized
to receive either high-dose (300 mg) or low-dose (100 mg) allopuri-
nol or matching placebo on a 1:1:1 basis for 6 weeks. The
randomization code was kept in the pharmacy department of the
Western Infirmary Hospital and was not broken until all follow-up
was complete. Those with clinically apparent infection, subsequently
corroborated with elevated C-reactive protein, were excluded from
the analyses of inflammatory parameters (this was decided before
analysis and unblinding of the study).
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The study was approved by the local research ethics committee.
All participants gave written informed consent. All study visits took
place in the Acute Stroke Unit at the Western Infirmary Hospital
Glasgow.
Demographic details and assessment of stroke severity were
obtained at baseline and blood was drawn to measure UA, ICAM,
C-reactive protein (CRP) and interleukin-6 (IL-6) levels. This was
repeated at 1 and 6 weeks from randomization.
ICAM-1 was measured in citrated plasma stored at 80°C using
high-sensitivity commercial enzyme-linked immunosorbent assay
kits (R&D Systems). CRP was measured using a high-sensitivity,
2-site enzyme-linked immunoassay. IL-6 was measured by a high-
sensitivity commercial enzyme-linked immunosorbent assay (R&D
Systems).
Statistical Analysis
Our primary end point was change in UA levels at 6 weeks.
Secondary end points were change in ICAM-1, CRP, and IL-6 levels
at 1 and 6 weeks. We calculated that 13 subjects per group would be
required to detect a 0.18-mmol/L difference in UA concentration
between groups with 90% power. We assumed a SD of 0.13 mmol/L
in UA levels. We anticipated a 10% to 15% dropout rate and further
losses due to mortality so we aimed to recruit 50 patients in total.
Analysis of variance, 2-sample t tests, or their nonparametric
equivalents were used for all statistical analyses (Minitab v15;
Minitab Inc). A general linear model was applied to adjust for
differences in baseline levels of key variables.
Results
In total, 50 patients were recruited (17 each in the high- and
low-dose groups and 16 in the placebo group). Half were
male, mean (SD) age was 70 (13) years, and median
baseline National Institutes of Health Stroke Scale score was
3 (interquartile range, 2 to 4). Groups were well matched.
Demographic details, including baseline UA, ICAM-1, CRP,
and IL-6, are displayed in Table 1.
No serious adverse events occurred. Two patients stopped
treatment in each of the low-dose and placebo groups. In each
group, one stopped treatment because of gastrointestinal
upset and one due to the required introduction of warfarin
therapy. One patient stopped treatment in the high-dose
allopurinol group due to requirement for azathioprine therapy
(deemed a contraindication to allopurinol use). All those in
the high-dose group completed follow-up, although one
patient did not have a 6-week UA level measured. One patient
in the low-dose group and 3 patients in the placebo group
(including the 2 withdrawals from treatment) did not com-
plete follow-up (Figure).
Of those who completed follow-up, 3 patients from the
placebo group, 2 from the low-dose group, and one from the
high-dose group were excluded from analyses of change in
inflammatory markers (clinically apparent infection and base-
line CRP of 20 mg/L for all).
Uric Acid Levels
UA levels at baseline and 6 weeks are shown for all groups in
Table 2. Average UA levels changed little in the placebo and
low-dose groups but fell significantly in the high-dose group
by 0.14 mmol/L at 6 weeks (P0.002 for difference between
groups on Kruskal-Wallis test; 95% CI for the difference
between the high-dose and placebo groups 0.19 mmol/L to
0.06 mmol/L on Mann-Whitney test).
Intercellular Adhesion Molecule-1 Levels
Mean ICAM-1 concentration rose by 51.2 ng/mL in the
placebo group, rose slightly (by 10.6 ng/mL) in the low-dose
allopurinol group, but fell in the high-dose group (by 2.6
ng/mL; difference between groups P0.012, Kruskal-Wallis
test; Table 2). A general linear model was applied to adjust
for differences in baseline ICAM-1 concentration and showed
that the differences between groups persisted and that base-
line ICAM-1 levels were not associated with change in
ICAM-1 level (P0.028 for differences between groups and
P0.24 for differences in baseline ICAM-1 level). There
were no statistically significant differences between groups at
1 week (data not shown). When all patients, including those
with clinical infection and elevated baseline CRP were
included in a post hoc sensitivity analysis, the median
Table 1. Demographic and Baseline Variables
Placebo Low Dose High Dose
Age, years, mean (SD) 69 (14) 70 (14) 71 (11)
Male sex, no. (%) 6 (46) 6 (43%) 6 (38%)
Stroke subtype, no. (%)
PACS 7 (44%) 11 (65%) 7 (41%)
LACS 8 (50%) 6 (35%) 9 (53%)
POCS 1 (6%) 0 1 (6%)
Thiazide use 3 (23%) 4 (29%) 2 (12%)
Diabetes 3 (23%) 3 (21%) 0
Baseline UA, mmol/L 0.34 0.34 0.35
Baseline ICAM-1, ng/mL 206.7 (167.4–255.2) 217 (193.9–297.6) 250.2 (159.9–322.1)
Baseline CRP, mg/L 3.59 (2.37–6.25) 1.61 (1.26–18.11 3.75 (1–11.45)
Baseline IL-6, pg/mL 4.23 (1.87–9.09) 4.09 (2.2–11.61) 4.02 (3.34–5.9)
Values shown are median (interquartile range) unless otherwise stated. The baseline levels of
inflammatory markers shown exclude those with elevated baseline CRP and clinical evidence of
infection.
PACS indicates partial anterior circulation syndrome; LACS, lacunar syndrome; POCS, posterior
circulation syndrome.
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changes seen in ICAM-1 levels were similar (41.79, 2.54, and
2.66 ng/mL in the placebo, low- and high-dose groups,
respectively), but the difference did not reach statistical
significance (P0.213 on Kruskal-Wallis test). Three pa-
tients in the placebo group had markedly elevated baseline
CRP levels (165.8, 3099, and 37.1 ng/mL, respectively) and
had among the highest levels of soluble ICAM-1 and thus the
largest falls.
C-Reactive Protein and Interleukin-6 Levels
CRP and IL-6 levels did not change in any group and there
were no significant differences between groups (Table 2).
Stroke Severity
Median change in National Institutes of Health Stroke Scale
score at 6 weeks was 1 in all groups (P0.3 on Kruskal-
Wallis test).
Discussion
Our results suggest that allopurinol attenuates the rise in the
proinflammatory marker soluble ICAM-1 seen after acute
ischemic stroke. This is the first evidence of a beneficial
effect of allopurinol on surrogate markers of vascular and
metabolic health after stroke. Our results also show that to
achieve sustained reduction in serum UA in the poststroke
period, a 300-mg dose of allopurinol is required. We saw a
0.14-mmol/L reduction in serum UA, which is well within a
potentially beneficial range.1,2
A number of large, well-conducted epidemiological studies
support the hypothesis that elevated serum UA is a powerful
predictor of increased risk of cardiovascular event rate and
mortality.1,7 Small increments in UA are associated with
reduced likelihood of favorable 90-day outcome and in-
creased risk of recurrent vascular events,2,3 although others
hypothesize that the antioxidant effects of increasing UA are
associated with improved outcome in the peri-infarct period.4
Furthermore, a small study of 24 patients has recently shown
that administration of UA within hours of ictus in those
treated with thrombolytic therapy for ischemic stroke yields
lower lipid peroxidation.9 This potential conflict with our data
is interesting and warrants further evaluation because at
present, no firm conclusions can be drawn. It is entirely
plausible that chronic elevations in serum UA could convey
harm but that the potential antioxidant effects of UA itself can
be harnessed in acute ischemia and oxidative stress. How-
ever, as much, if not more, data exist to support pursuit of
UA-lowering strategies after stroke. Data exist to support
harmful effects of UA on platelet, smooth muscle, and
endothelial function.7 Equally, recent post hoc analyses of the
Losartan Intervention For End point reduction (LIFE) study
suggest UA reduction impacts favorably on cardiovascular
risk. Perhaps more convincingly, interventional studies of
xanthine oxidase inhibition, which will reduce both UA and
oxidative stress, consistently show benefits on measures of
endothelial function in patients with or at high risk of
vascular disease.7 This is of interest because several drugs are
routinely used to lower UA in other conditions.
However, the previously witnessed effect of allopurinol
may relate more to xanthine oxidase inhibition per se and a
reduction in oxidative stress than to UA reduction.10 It is of
course possible that elevated UA may signal harm as an
indirect marker of greater pro-oxidative stress rather than
being a direct toxic agent. Clearly, more studies are needed to
disentangle the causal mechanisms, but our data support this;
we saw little impact on UA levels with low-dose allopurinol
Figure. Randomization and patient flow chart.
Table 2. Change in Blood Markers at 6 Weeks
Placebo Low Dose High Dose P Value
Change in UA 0.02 0.02 0.14 0.002
Change in ICAM-1 51.2 10.6 2.6 0.012
Change in CRP 2.33 0.48 0.28 0.9
Change in IL-6 1.52 0.80 0.36 0.5
Kruskal-Wallis test was used to evaluate median change in parameters.
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but saw a similar, albeit smaller, effect on inflammatory
markers to that of high dose. Importantly, however, it remains
possible that reducing UA will yield benefits through, for
example, changes in smooth muscle function in the longer
term. Either way, our data show allopurinol may be of use and
can be used safely in the early postinfarct period.
We did not see any differences in neurological recovery, as
suggested by some animal work.11 However, we would not
expect to detect neurological benefit in a small pilot study in
which patients were randomized up to 3 days after ictus and
were so mildly affected pretreatment.
Allopurinol has recently been shown to inhibit expression
of ICAM-1 in vitro.8 Our study is the first to evaluate this in
patients with acute stroke. Soluble ICAM-1 expression is
increased when endothelium is activated or damaged and
levels are known to rise after acute stroke,12,13 although there
are inconsistencies in the literature,14 and rises are also linked
to early neurological deterioration.15 The fact that the rise in
ICAM-1 levels appears attenuated by allopurinol is encour-
aging; levels are known to be reduced by other effective
therapies.16 There may also be longer-term benefits; increased
plasma concentrations of ICAM-1 are associated with both
symptomatic carotid atherosclerosis17 and subcortical vascu-
lar disease18 suggesting that measures to attenuate levels
could help patients with any type of cerebrovascular disease.
Moreover, recent studies suggest elevated ICAM-1 is a
particularly strong predictor of incident type 2 diabetes,19,20
whereas other evidence supports a link between elevated UA
and diabetes.21 Thus, future studies should address whether
allopurinol has potential to attenuate progression to diabetes
in the poststroke period and more generally.
We excluded those with clinical infection and elevated
CRP from analyses of inflammatory markers. This was
decided before study completion and when the study was
blinded because we anticipated that many would sustain
infection. More patients had infection with marked base-
line CRP elevation in the placebo group. Unsurprisingly,
all exhibited marked falls in inflammatory markers as
infection resolved. When these participants were included
in post hoc sensitivity analyses, the differences between
the groups were again in favor of a beneficial effect of
allopurinol, although statistical significance was not
reached.
We saw no differences in CRP and IL-6 levels among
groups and no change in their levels in the poststroke
period. Equally, there were no differences in ICAM-1
levels by 1 week, but levels had risen significantly in the
placebo group by 6 weeks. Others have demonstrated an
early rise in CRP levels, which, in one study, began to
decline at 1 week.14 It is possible that we have missed an
early CRP rise (and possibly a rise in IL-6) by the sampling
intervals we chose. However, overall, we are reassured by
the similarities among groups on all baseline measures and
by the dose–response relationship we saw and feel that our
results reflect a genuine effect of allopurinol treatment. We
must however caution that our findings should be sup-
ported by future work to link allopurinol use to improve-
ments in other measures of endothelial function such as
cerebrovascular reactivity or, for example, carotid intima
media thickness.
In summary, our data provide the first evidence of a
beneficial effect of allopurinol on surrogate markers of
vascular and metabolic health after stroke and are encourag-
ing. We have demonstrated a safe dose-dependent reduction
in UA after allopurinol use together with an attenuated rise in
ICAM-1, both changes that encourage further investigation of
the benefits of allopurinol after stroke.
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